Regen Biopharma, Inc. (OTC: RGBP) is a company that is working in the rather precarious and nascent field of cancer research, delving into therapy as well as treatment for autoimmune diseases. RGBP is a publicly traded company that has a highly recognizable stock symbol, and as of late, its stock has been rising because of the fact that it has been making a lot of advances in the field that it is involved in. It is widely known for the advancements it has made so far, but as of late, these advancements have been moving at a rapid pace.
The primary area in which RGBP is investing most of its research manpower is treating cancer and autoimmune disorders through the modulation and modification of the small molecules of cancerous growths as well as the substances that are creating the immune system imbalance. Perhaps the most telling sign that this therapy is going to make waves is the fact that the animal trials have gone extremely well. Lab mice were given the maximum allowed dosage to check for any signs of toxicity and the researchers were pleased to find that no signs of such an overdose were detected!
This has prompted the market to have a lot of faith in what Regen Biopharma, Inc. (OTC: RGBP) has to offer, giving the shareholders that have been patiently waiting for the company to have a breakthrough that gives them cause to celebrate. While it is true that RGBP has been making advancements since its very inception, one of the biggest hurdles faced by pretty much any entity that is attempting to research diseases and figure out how they might be cured, was the safety of the treatments that were being researched.
Now that safety has been proven to an extent, Regen Biopharma, Inc. (OTC: RGBP) could swiftly be cleared for human trials. The great thing about human trials is that if things get to that point, it is more likely that the treatment in question is going to end up getting approved than being rejected. After all, it is more difficult for a treatment to get past testing on lab mice to human trials than for it to get from human trials to the point where it is finally allowed to be sold to people. That being said, the road that stretched long and hard before RGBP is shortening up immensely. There are still a few steps to conquer before the drug is approved for widespread sale but RGBP is closing the gap.
Still, the recent victory is certainly something to celebrate, especially because of the fact that it is allowing Regen Biopharma, Inc. (OTC: RGBP) to get the attention of the Big boys or large Biophama firms. Their website, https://www.regenbiopharmainc.com/ has a lot of different bits of info on their current progress; it is a great place to find out what is happening with the new treatment. If this little Biopharma does what they expect to, look for them on the big board Nasdaq in the very near future.